Artivion, Inc.
HealthcareNYSE:AORT · New York Stock Exchange
-$0.50 today
Vol 0.48M · Avg 0.62M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
2.2%
avg -2.0%
ROIC
2.2%
avg 2.1%
ROA
1.1%
avg -0.5%
Analysis
ROIC is currently the strongest return metric at 2.2% versus its period average of 2.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James Patrick Mackin | Chairman, President & Chief Executive Officer | $1.88M | — | 59 | $76,223.00 | 0.16% |
Lance A. Berry | EVice President, Chief Operating Officer, Chief Financial Officer & Treasurer | $1.02M | — | 54 | $210,827.00 | 0.43% |
John E. Davis | Senior Vice President & Chief Commercial Officer | $723,070.00 | — | 61 | $230,794.00 | 0.48% |
Jean F. Holloway | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | $719,596.00 | — | 69 | $185,095.00 | 0.38% |
Simona Zannetti | Senior Vice President of Clinical Research & Chief Medical Officer | $693,621.00 | — | — | — | — |
Amy D. Horton | Vice President & Chief Accounting Officer | $621,265.00 | — | 56 | $139,088.00 | 0.29% |
Andrew Green | Senior Vice President of Regulatory & Quality | — | — | 57 | $0.00 | <0.01% |
Jason D. Asper | Senior Vice President and Chief Strategy & Digital Officer | — | — | 50 | — | — |
Matthew A. Getz | Vice President of Human Resources & Chief Human Resources Officer | — | — | 57 | $36,678.00 | 0.08% |
Robert C. Thomson | Vice President of Research & Development | — | — | 55 | $13,291.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
68
$21.96M
Net Sentiment
$21.96M
Net selling
Most Active
Stanton Marshall S.
20 transactions
1–10 of 68
Analysis
Insiders reported 0 buys worth $0.00 and 68 sells worth $21.96M over the last 12 months. That adds up to net selling of $21.96M. Stanton Marshall S. was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -20.6% | +17.5% (15yr)2 analysts |
| Revenue | N/A | N/A | +3.5% | +11.7% (15yr)3 analysts |
| Net Income | N/A | N/A | -20.4% | +21.5% (15yr)3 analysts |
| EBIT | N/A | N/A | -24.8% | +10.5% (15yr)3 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.5% over three years. Forward estimates point to Net Income at +21.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
LifeStance Health Group, Inc.
NASDAQ:LFST
$3.30B
Brookdale Senior Living Inc.
NYSE:BKD
$3.21B
Integer Holdings Corporation
NYSE:ITGR
$3.09B
Addus HomeCare Corporation
NASDAQ:ADUS
$1.74B
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
$1.46B
Ardent Health Partners, LLC
NYSE:ARDT
$1.34B
Inspire Medical Systems, Inc.
NYSE:INSP
$1.23B
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
Who manages AORT?
Artivion, Inc. (AORT) lists 10 active executives. The top listed executive is Jean F. Holloway, Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary.
Are AORT insiders buying or selling?
Recent insider activity shows net selling of $28.10M.
Explore More
Continue the stock analysis
Jump to another research area for this company.